資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/30554
|
題名: | Molecular basis of weak D in Taiwanese |
作者: | Lin, IL;Shih, MC;Hsieh, MH;Liu, TC;Chang, SE;Lin, CL;Chang, JG |
貢獻者: | 附設醫院醫研部;China Med Coll & Hosp, Dept Mol Med, Taichung, Taiwan;China Med Coll & Hosp, Dept Lab Med, Taichung, Taiwan;Kaohsiung Med Univ, Blood Bank, Dept Med Technol, Kaohsiung, Taiwan;Taichung Blood Transfus Ctr, Taichung, Taiwan |
日期: | 2003 |
上傳時間: | 2010-09-24 14:57:36 (UTC+8) |
出版者: | SPRINGER-VERLAG |
摘要: | Patients with beta-thalassemia major still suffer growth retardation. After excluding patients with cortisol deficiency, hypothyroidism, hypogonadism, delayed puberty, malnutrition, severe congestive heart failure, and severely impaired liver function, 29 patients were enrolled in this study. Fifteen (52%) patients exhibited growth retardation and underwent two growth hormone (GH) provocation tests. Eight (53%) of the 15 patients had GH deficiency and were subsequently treated with subcutaneous recombinant human GH (Genotropin, Pharmacia Corporation, Sweden). Growth velocity increased from the pretreatment rate of 3.1+/-0.4 cm/year to 7.1+/-1.6 cm/yr (p<0.001) after 1 year and to 6.8+/-1.3 cm/year (p<0.001) after 2 years. Patients with growth retardation had lower insulin like growth factor-1 (p=0.001) and insulin like growth factor binding protein-3 (p=0.003) levels than those without growth retardation. In patients with beta-thalassemia major, growth retardation is a common complication and GH deficiency plays an important role. Thalassemic patients with GH deficiency can safely increase their growth velocity with recombinant human GH for2 years; however, the effect on final height still needs to be determined. |
關聯: | ANNALS OF HEMATOLOGY 82(10):617-620 |
顯示於類別: | [台中附設醫院] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|